These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 15895440)
21. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Miettinen M; Lasota J Pol J Pathol; 2003; 54(1):3-24. PubMed ID: 12817876 [TBL] [Abstract][Full Text] [Related]
22. Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor. Zheng S; Pan YL; Tao DY; Wang JL; Huang KE Scand J Gastroenterol; 2009; 44(6):760-3. PubMed ID: 19096980 [TBL] [Abstract][Full Text] [Related]
23. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Haller F; Detken S; Schulten HJ; Happel N; Gunawan B; Kuhlgatz J; Füzesi L Ann Surg Oncol; 2007 Feb; 14(2):526-32. PubMed ID: 17139461 [TBL] [Abstract][Full Text] [Related]
24. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib. Loughrey MB; Trivett M; Beshay V; Dobrovic A; Kovalenko S; Murray W; Lade S; Turner H; McArthur GA; Zalcberg J; Waring PM Histopathology; 2006 Jul; 49(1):52-65. PubMed ID: 16842246 [TBL] [Abstract][Full Text] [Related]
25. Extragastrointestinal stromal tumors presenting as vulvovaginal/rectovaginal septal masses: a diagnostic pitfall. Lam MM; Corless CL; Goldblum JR; Heinrich MC; Downs-Kelly E; Rubin BP Int J Gynecol Pathol; 2006 Jul; 25(3):288-92. PubMed ID: 16810068 [TBL] [Abstract][Full Text] [Related]
27. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. Tarn C; Merkel E; Canutescu AA; Shen W; Skorobogatko Y; Heslin MJ; Eisenberg B; Birbe R; Patchefsky A; Dunbrack R; Arnoletti JP; von Mehren M; Godwin AK Clin Cancer Res; 2005 May; 11(10):3668-77. PubMed ID: 15897563 [TBL] [Abstract][Full Text] [Related]
28. Role of surgery combined with kinase inhibition in the management of gastrointestinal stromal tumor (GIST). Hohenberger P; Eisenberg B Ann Surg Oncol; 2010 Oct; 17(10):2585-600. PubMed ID: 20407930 [TBL] [Abstract][Full Text] [Related]
30. Gastrointestinal stromal tumors. von Mehren M; Watson JC Hematol Oncol Clin North Am; 2005 Jun; 19(3):547-64, vii. PubMed ID: 15939196 [TBL] [Abstract][Full Text] [Related]
31. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor. Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK Oncology; 2009; 76(5):326-32. PubMed ID: 19307738 [TBL] [Abstract][Full Text] [Related]
32. Clinicopathological features of gastric stromal tumors. Nishida T; Nakamura J; Taniguchi M; Hirota S; Ito T; Kitamura Y; Matsuda H J Exp Clin Cancer Res; 2000 Dec; 19(4):417-25. PubMed ID: 11277317 [TBL] [Abstract][Full Text] [Related]
33. Successes and challenges in translational research: the development of targeted therapy for gastrointestinal stromal tumours. Renouf DJ; Wilson L; Blanke CD Clin Cancer Res; 2009 Jun; 15(12):3908-11. PubMed ID: 19509180 [TBL] [Abstract][Full Text] [Related]
34. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate. McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774 [TBL] [Abstract][Full Text] [Related]
35. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Mussi C; Schildhaus HU; Gronchi A; Wardelmann E; Hohenberger P Clin Cancer Res; 2008 Jul; 14(14):4550-5. PubMed ID: 18628470 [TBL] [Abstract][Full Text] [Related]
36. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining. Lee HE; Kim MA; Lee HS; Lee BL; Kim WH J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383 [TBL] [Abstract][Full Text] [Related]
37. [Treatment of metastatic gastrointestinal stromal tumors with Imatinib: report of four cases]. Garrido S M; Moneada M M; Tapia N G; Méndez O G; Galindo A H; Huete G A; Ibáñez A L; González S; Alvarez Z M Rev Med Chil; 2007 Oct; 135(10):1327-32. PubMed ID: 18180842 [TBL] [Abstract][Full Text] [Related]
38. [New orientations in the management of advanced, metastatic gastrointestinal stromal tumors (GIST): combination of surgery and systemic therapy with imatinib in a case of primary gastric location]. Catani M; De Milito R; Simi M Chir Ital; 2005; 57(1):127-33. PubMed ID: 15832750 [TBL] [Abstract][Full Text] [Related]
39. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Agaimy A; Wünsch PH; Hofstaedter F; Blaszyk H; Rümmele P; Gaumann A; Dietmaier W; Hartmann A Am J Surg Pathol; 2007 Jan; 31(1):113-20. PubMed ID: 17197927 [TBL] [Abstract][Full Text] [Related]
40. [At last, an effective therapy for non-differentiated GI sarcomas (gastro intestinal stromal tumor)]. Des Guetz G; De Mestier P; Pierga JY J Chir (Paris); 2002 Oct; 139(5):268-73. PubMed ID: 12410126 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]